CiMAb. Monoclonal antibodies
CiMAb.
A new promising antibody with
approx. 15-fold improved anti-cancer effect.
CIBEX enables the production of antibodies (MAbs) which have a unique, fucose-free glycan pattern that leads to enhanced effector function.
Ciliates provide a unique and unusual glycan pattern
(e.g. CiMAb C2B8):
fucose-free
two-antenna core structure with up to 5 mannoses
terminal glucoses
Typical mammalian glycan pattern
(e.g. MabThera ®, only the most frequent forms are depicted)
